Safety, Tolerability, and Pharmacokinetics of Adrenomedullin in Healthy Males: A Randomized, Double-Blind, Phase 1 Clinical Trial.

Toshihiro KitaYoshikazu KajiKazuo Kitamura

Published in: Drug design, development and therapy (2020)

This is the first phase 1 trial in healthy men evaluating the safety of AM. Our results demonstrate the safety and tolerability of AM for subsequent Phase 2 trials.

Keyphrases

double blind
clinical trial
open label
placebo controlled
middle aged